Antidepressant effect of pramipexole in mice forced swimming test: A cross talk between dopamine receptor and NMDA/nitric oxide/cGMP pathway

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 295-304

  Ostadhadi, Sattar ^a,b   Imran Khan, Muhammad ^b   Norouzi Javidan, Abbas ^a   Dehpour, Ahmad Reza ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Depression; Dopamine D2 receptor; Forced swimming test; Mice; Nitric oxide; NMDA; Pramipexole

Indexed keywords

7 NITROINDAZOLE; ARGININE; CYCLIC GMP; DIZOCILPINE; DOPAMINE RECEPTOR; FLUOXETINE; HALOPERIDOL; METHYLENE BLUE; N METHYL DEXTRO ASPARTIC ACID; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PRAMIPEXOLE; SILDENAFIL; SULPIRIDE; ANTIDEPRESSANT AGENT; BENZOTHIAZOLE DERIVATIVE; DIZOCILPINE MALEATE; N METHYLASPARTIC ACID;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; FORCED SWIM TEST; IMMOBILITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG EFFECTS; IMMOBILIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; BENZOTHIAZOLES; CYCLIC GMP; DIZOCILPINE MALEATE; HALOPERIDOL; IMMOBILIZATION; INJECTIONS, INTRAPERITONEAL; MALE; METHYLENE BLUE; MICE; MOTOR ACTIVITY; N-METHYLASPARTATE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION; SILDENAFIL CITRATE; SWIMMING;

EID: 84963959944     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.04.026     Document Type: Article

References (81)

1. Blier P., De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 1994, 15(7):220-226.
2. Briley M., Moret C. Neurobiological mechanisms involved in antidepressant therapies. Clin. Neuropharmacol. 1993, 16(5):387-400.
3. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1994.
4. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol. 2006, 16(6):391-402.
5. Willner P., Hale A.S., Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J. Affect. Disord. 2005, 86(1):37-45.
6. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 2000, 405(1):365-373.
7. Klimke A., Larisch R., Janz A., Vosberg H., Müller-Gärtner H.-W., Gaebel W. Dopamine D 2 receptor binding before and after treatment of major depression measured by [123 I] IBZM SPECT. Psychiatry Res.: Neuroimaging 1999, 90(2):91-101.
8. Paolo S., Collu M., Pani L., Gessa G.L., Serra G. Antidepressant-like effect of selective dopamine D 1 receptor agonists in the behavioural despair animal model of depression. Eur. J. Pharmacol. 1994, 262(1):107-111.
9. Yamada J., Sugimoto Y., Yamada S. Involvement of dopamine receptors in the anti- immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur. J. Pharmacol. 2004, 504(3):207-211.
10. Renard C.E., Fiocco A.J., Clenet F., Hascoet M., Bourin M. Is dopamine implicated in the antidepressant- like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology 2001, 159(1):42-50.
11. Borsini F., Lecci A., Mancinelli A., D'Aranno V., Meli A. Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity. Eur. J. Pharmacol. 1988, 148(3):301-307.
12. Vaugeois J.-M., Pouhé D., Zuccaro F., Costentin J. Indirect dopamine agonists effects on despair test: dissociation from hyperactivity. Pharmacol. Biochem. Behav. 1996, 54(1):235-239.
13. Barone P., Poewe W., Albrecht S., Debieuvre C., Massey D., Rascol O., et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9(6):573-580.
14. Lattanzi L., Dell'Osso L., Cassano P., Pini S., Rucci P., Houck P.R., et al. Pramipexole in treatment-resistant depression: a 16- week naturalistic study. Bipolar Disord. 2002, 4(5):307-314.
15. Inoue T., Kitaichi Y., Masui T., Nakagawa S., Boku S., Tanaka T., et al. Pramipexole for stage 2 treatment- resistant major depression: an open study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(8):1446-1449.
16. El-Mallakh R.S., Penagaluri P., Kantamneni A., Gao Y., Roberts R.J. Long- term use of pramipexole in bipolar depression: a naturalistic retrospective chart review. Psychiatr. Q. 2010, 81(3):207-213.
17. Siuciak J.A., Fujiwara R.A. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors. Psychopharmacology 2004, 175(2):163-169.
18. Rogoz Z., Skuza G. Mechanism of synergistic action following co- treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol. Rep.: PR 2005, 58(4):493-500.
19. Schulte-Herbrüggen O., Vogt M.A., Hörtnagl H., Gass P., Hellweg R. Pramipexole is active in depression tests and modulates monoaminergic transmission, but not brain levels of BDNF in mice. Eur. J. Pharmacol. 2012, 677(1):77-86.
20. Edwards S., Simmons D.L., Galindo D.G., Doherty J.M., Scott A.M., Hughes P.D., et al. Antagonistic effects of dopaminergic signaling and ethanol on protein kinase A-mediated phosphorylation of DARPP-32 and the NR1 subunit of the NMDA receptor. Alcohol.: Clin. Exp. Res. 2002, 26(2):173-180.
21. 2+ influx by D2 dopamine and A2A adenosine receptors. Nat. Neurosci. 2010, 13(8):958-966.
22. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7(5):426-437.
23. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 1999, 375(1):31-40.
24. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62(11):1310-1316.
25. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47(4):351-354.
26. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63(8):856-864.
27. Haj-Mirzaian A., Ostadhadi S., Kordjazy N., Dehpour A.R., Mehr S.E. Opioid/NMDA receptors blockade reverses the depressant-like behavior of foot shock stress in the mouse forced swimming test. Eur. J. Pharmacol. 2014, 735:26-31.
28. Kordjazy N., Haj-Mirzaian A., Amiri S., Ostadhadi S., Amini-khoei H., Dehpour A.R. Involvement of N-methyl-d-aspartate receptors in the antidepressant-like effect of 5-hydroxytryptamine 3 antagonists in mouse forced swimming test and tail suspension test. Pharmacol. Biochem. Behav. 2016, 141:1-9.
29. Ostadhadi S., Khan M.I., Norouzi-Javidan A., Chamanara M., Jazaeri F., Zolfaghari S., et al. Involvement of NMDA receptors and l-arginine/nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effects of topiramate in mice forced swimming test. Brain Res. Bull. 2016, 122:62-70.
30. Haj-Mirzaian A., Kordjazy N., Haj-Mirzaian A., Ostadhadi S., Ghasemi M., Amiri S., et al. Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. Psychopharmacology 2015, 232(19):3551-3561.
31. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res. Rev. 2000, 32(2):476-509.
32. Esplugues J.V. NO as a signalling molecule in the nervous system. Br. J. Pharmacol. 2002, 135(5):1079-1095.
33. Mantovani M., Pértile R., Calixto J.B., Santos A.R., Rodrigues A.L.S. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci. Lett. 2003, 343(1):1-4.
34. Joca S.R.L., Guimarães F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006, 185(3):298-305.
35. Kaster M.P., Ferreira P.K., Santos A.R., Rodrigues A.L. Effects of potassium channel inhibitors in the forced swimming test: possible involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav. Brain Res. 2005, 165(2):204-209.
36. Harkin A., Connor T.J., Burns M.P., Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur. Neuropsychopharmacol. 2004, 14(4):274-281.
37. Haj-Mirzaian A., Kordjazy N., Amiri S., Haj-Mirzaian A., Amini-khoei H., Ostadhadi S., et al. Involvement of nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tropisetron and ondansetron in mice forced swimming test and tail suspension test. Eur. J. Pharmacol. 2016.
38. Ostadhadi S., Kordjazy N., Haj-Mirzaian A., Ameli S., Akhlaghipour G., Dehpour A. Involvement of NO/cGMP pathway in the antidepressant-like effect of gabapentin in mouse forced swimming test. Naunyn-Schmiedeberg's Arch. Pharmacol. 2016, 1-10.
39. Cryan J.F., Slattery D.A. Animal models of mood disorders: recent developments. Curr. Opin. Psychiatry 2007, 20(1):1-7.
40. Kordjazy N., Haj-Mirzaian A., Amiri S., Ostadhadi S., Kordjazy M., Sharifzadeh M., et al. Elevated level of nitric oxide mediates the anti- depressant effect of rubidium chloride in mice. Eur. J. Pharmacol. 2015, 762:411-418.
41. Ostadhadi S., Haj-Mirzaian A., Nikoui V., Kordjazy N., Dehpour A.R. Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice. Clin. Exp. Pharmacol. Physiol. 2015, 43:203-212.
42. Porsolt R., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Thér. 1977, 229(2):327-336.
43. Haj-Mirzaian A., Kordjazy N., Ostadhadi S., Amiri S., Haj-Mirzaian A., Dehpour A.-R. Fluoxetine reverses the behavioral despair induced by neurogenic stress in mice: role of N-methyl d-aspartate and opioid receptors. Can. J. Physiol. Pharmacol. 2016, 14:1-14.
44. Wang R., Xu Y., Wu H.-L., Li Y.-B., Li Y.-H., Guo J.-B., et al. The antidepressant effects of curcumin in the forced swimming test involve 5 -HT 1 and 5-HT 2 receptors. Eur. J. Pharmacol. 2008, 578(1):43-50.
45. Li Y., Zhu Z.R., Ou B.C., Wang Y.Q., Tan Z.B., Deng C.M., et al. Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test. Behav. Brain Res. 2015, 279:100-105.
46. Dhir A., Kulkarni S. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur. J. Pharmacol. 2007, 568(1):177-185.
47. Brown A., Gershon S. Dopamine and depression. J. Neural Transm./Gen. Section JNT 1993, 91(2-3):75-109.
48. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol. Psychiatry 1992, 32(1):1-17.
49. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam. Clin. Pharmacol. 2004, 18(6):601-607.
50. Rossetti Z.L., Lai M., Hmaidan Y., Gessa G.L. Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine. Eur. J. Pharmacol. 1993, 242(3):313-315.
51. Joca S.R., Skalisz L.L., Beijamini V., Vital M.A.B., Andreatini R. The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur. Neuropsychopharmacol. 2000, 10(4):223-228.
52. Maj J., Rogoz Z. Synergistic effect of pramipexole and sertraline in the forced swimming test. Pol. J. Pharmacol. 1998, 51(6):471-475.
53. Shopsin B., Gershon S. Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495). Neuropsychobiology 1978, 4(1):1-14.
54. Wæhrens J., Gerlach J. Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in out-patients. J. Affect. Disord. 1981, 3(2):193-202.
55. Wang M., Wong A.H., Liu F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res. 2012, 1476:154-163.
56. Ferraro L., O'Connor W.T., Beggiato S., Tomasini M.C., Fuxe K., Tanganelli S., et al. Striatal NTS1, dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release-a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat. Eur. J. Neurosci. 2012, 35(2):207-220.
57. Leveque J.-C., Macías W., Rajadhyaksha A., Carlson R.R., Barczak A., Kang S., et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J. Neurosci. 2000, 20(11):4011-4020.
58. Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., et al. Fyn is required for haloperidol- induced catalepsy in mice. J. Biol. Chem. 2006, 281(11):7129-7135.
59. Kotecha S.A., Oak J.N., Jackson M.F., Perez Y., Orser B.A., Van Tol H.H., et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 2002, 35(6):1111-1122.
60. Khan M.I., Ostadhadi S., Zolfaghari S., Mehr S.E., Hassanzadeh G., Dehpour A.-R. The involvement of NMDA receptor/NO/cGMP pathway in the antidepressant like effects of baclofen in mouse force swimming test. Neurosci. Lett. 2016, 612:52-61.
61. de Souza Brocardo P., Budni J., Lobato K.R., Kaster M.P., Rodrigues A.L.S. Antidepressant-like effect of folic acid: Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur. J. Pharmacol. 2008, 598(1):37-42.
62. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2008, 32(1):140-144.
63. Paul I.A., Skolnick P. Glutamate and depression. Ann. N. Y. Acad. Sci. 2003, 1003(1):250-272.
64. Ghasemi M., Montaser-Kouhsari L., Shafaroodi H., Nezami B.G., Ebrahimi F., Dehpour A.R. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology 2009, 206(2):325-333.
65. Ghasemi M., Raza M., Dehpour A. NMDA receptor antagonists augment antidepressant- like effects of lithium in the mouse forced swimming test. J. Psychopharmacol. 2009.
66. Rogóz Z., Skuza G., Maj J., Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002, 42(8):1024-1030.
67. Boyce-Rustay J.M., Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice. Neuropsychopharmacology 2006, 31(11):2405-2414.
68. Ledo A., Frade J., Barbosa R.M., Laranjinha J. Nitric oxide in brain: diffusion, targets and concentration dynamics in hippocampal subregions. Mol. Aspects Med. 2004, 25(1):75-89.
69. Moncada S., Bolaños J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 2006, 97(6):1676-1689.
70. da Silva GdL.Matteussi A.S., dos Santos A.R.S., Calixto J.B., Rodrigues A.L.S. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 2000, 11(17):3699-3702.
71. Harkin A., Connor T., Walsh M., St.John N., Kelly J. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44(5):616-623.
72. Yildiz F., Erden B.F., Ulak G., Utkan T., Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 2000, 149(1):41-44.
73. Almeida R.C., Felisbino C.S., López M.G., Rodrigues A.L.S., Gabilan N.H. Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav. Brain Res. 2006, 168(2):318-322.
74. Kulkarni S.K., Dhir A. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur. J. Pharmacol. 2007, 569(1):77-83.
75. Kaster M.P., Rosa A.O., Santos A.R., Rodrigues A.L.S. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int. J. Neuropsychopharmacol. 2005, 8(04):601-606.
76. Dhir A., Kulkarni S. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(4):921-925.
77. Ghasemi M., Sadeghipour H., Mosleh A., Sadeghipour H.R., Mani A.R., Dehpour A.R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur. Neuropsychopharmacol. 2008, 18(5):323-332.
78. Volke V., Wegener G., Bourin M., Vasar E. Antidepressant-and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav. Brain Res. 2003, 140(1):141-147.
79. Denninger J.W., Marletta M.A. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim. Biophys. Acta (BBA)-Bioenerg. 1999, 1411(2):334-350.
80. Eroglu L., Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol. Res. 1997, 36(5):381-385.
81. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 1995, 75(4):725-748.